Consensus AbbVie Inc.

Equities

ABBV

US00287Y1091

Market Closed - Nyse Other stock markets 04:00:13 2024-04-15 pm EDT			5-day change	1st Jan Change
161.7 ^USD	-0.38%		-4.79%	+4.32%

Apr. 12	AbbVie Says Phase 3 Interim Data Support Long-Term Efficacy, Safety of Migraine Drug	MT
Apr. 12	AbbVie Inc. Announces Late-Breaking Data At Aan Supporting Long-Term Safety and Efficacy of Atogepant (Qulipta®) for Prevention of Migraine	CI

Evolution of the average Target Price on AbbVie Inc.

Price target over the last 5 years

History of analyst recommendation changes

4c1fa3de4d4.KhjgYN7u4ZhwukGNz4B1x7ZlQ3rxMcFawjNGhp08r5I.XyCjN7q01skBwg7mo9gyhuInFjSuZogwgFoL0OdynccZLNkSm4XY4ir3EA~68b615f978b163d25178051632649b66

Analyst Recommendations on AbbVie Inc.

Barclays Raises AbbVie Price Target to $195 From $185, Maintains Overweight Rating	Mar. 27	MT
Abbvie Insider Sold Shares Worth $3,716,757, According to a Recent SEC Filing	Mar. 22	MT
Abbvie Insider Sold Shares Worth $10,539,508, According to a Recent SEC Filing	Mar. 21	MT
ANALYST RECOMMENDATIONS : Abbvie, Align Technology; Ulta Beauty, United Airlines, Currys...	Mar. 15
ANALYST RECOMMENDATIONS : AbbVie, Doordash, Eli Lilly, Moderna, Hiscox...	Feb. 26
Mizuho Raises Price Target on Cerevel Therapeutics to $45 From $25 to Reflect Sale Price to AbbVie, Keeps Neutral Rating	Feb. 15	MT
UBS Adjusts Price Target on AbbVie to $172 from $165, Maintains Neutral Rating	Feb. 06	MT
Truist Adjusts Price Target on AbbVie to $195 From $180, Maintains Buy Rating	Feb. 06	MT
Piper Sandler Adjusts Price Target on AbbVie to $185 From $180, Maintains Overweight Rating	Feb. 05	MT
Morningstar Upgrades AbbVie to Hold From Sell, Increases Price Target to $168 From $137	Feb. 05	MT
Wells Fargo Adjusts Price Target on AbbVie to $200 From $180, Maintains Overweight Rating	Feb. 05	MT
Goldman Sachs Adjusts Price Target on AbbVie to $180 From $173, Keeps Buy Rating	Feb. 05	MT
BMO Capital Adjusts Price Target on AbbVie to $195 From $187, Maintains Outperform Rating	Feb. 05	MT
Barclays Adjusts Price Target on AbbVie to $185 From $175, Maintains Overweight Rating	Feb. 05	MT
Raymond James Adjusts Price Target on AbbVie to $189 From $181, Maintains Outperform Rating	Feb. 05	MT
Powell, the paper tiger	Feb. 05
ANALYST RECOMMENDATIONS : Abbvie, Microsoft, Tesla, Alphabet, Booking...	Feb. 05
Deutsche Bank Raises AbbVie Price Target to $170 From $150, Maintains Hold Rating	Jan. 29	MT
William Blair Upgrades AbbVie to Outperform From Market Perform	Jan. 29	MT
BofA Securities Raises AbbVie Price Target to $165 From $160, Maintains Neutral Rating	Jan. 26	MT
Barclays Raises AbbVie Price Target to $175 From $170, Maintains Overweight Rating	Jan. 23	MT
UBS Adjusts AbbVie Price Target to $165 From $150, Maintains Neutral Rating	Jan. 17	MT
Berenberg: M&A Dealmaking in Pharmaceutical Sector to Further Accelerate in 2024	Jan. 09	MT
AbbVie Says Phase 2 Trial of Lutikizumab Shows Higher Response Rates	Jan. 08	MT
Fed officials fail to calm investors	Dec. 20

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

162.3 USD

Average target price

184.3 USD

Spread / Average Target

+13.54%

High Price Target

206 USD

Spread / Highest target

+26.94%

Low Price Target

161 USD

Spread / Lowest Target

-0.79%

Consensus detail

Consensus revision (last 18 months)

Analysts covering AbbVie Inc.

Barclays
UBS
Truist Securities
Piper Sandler
Morningstar
Wells Fargo Securities
Goldman Sachs
BMO Capital
Raymond James
Deutsche Bank Securities
William Blair & Co.
BofA Securities
HSBC
Morgan Stanley
Guggenheim
Argus
Wolfe Research
Atlantic Equities
SVB Securities LLC
Credit Suisse
Societe Generale
Berenberg Bank
JPMorgan Chase
Cowen
Redburn
Mizuho Securities
SVB Leerink
Daiwa Securities
RBC Capital Markets

Ratings for AbbVie Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar